Tony Coles, the former CEO of Onyx Pharmaceuticals, and Professor Susan Lindquist of MIT’s Whitehead Institute in Cambridge, Massachusetts, have joined forces to found a new biotechnology company focused on neurodegenerative diseases. The company, called Yumanity Therapeutics, is based on approaches developed in Susan Lindquist’s laboratory to screen compounds that inhibit protein misfolding in yeasts and induced pluripotent stem cells (iPSCs) derived from patients. The company has already identified a lead compound for Parkinson’s disease, which is being tested in mouse models. Currently, the founders are funding the company themselves, but they are aiming to close a round of funding in early 2015.
Click here to read more.Share this: